Statera Biopharma, Inc. STAB
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 236.50K | 236.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 1.49M | 236.50K |
| Cost of Revenue | -- | -- | -- | 488.30K | 115.90K |
| Gross Profit | -- | -- | -- | 998.70K | 120.60K |
| SG&A Expenses | -- | -- | -- | 20.11M | 17.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | 32.43M | 24.81M |
| Operating Income | -- | -- | -- | -30.94M | -24.57M |
| Income Before Tax | -- | -- | -- | -101.88M | -28.86M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -- | -101.88 | -28.86 |
| Earnings from Discontinued Operations | -- | -- | -- | 0.00 | 0.00 |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | 24.30K | 13.40K |
| Net Income | -- | -- | -- | -101.85M | -28.84M |
| EBIT | -- | -- | -- | -30.94M | -24.57M |
| EBITDA | -- | -- | -- | -30.68M | -24.43M |
| EPS Basic | -- | -- | -- | -3.00 | -1.46 |
| Normalized Basic EPS | -- | -- | -- | -0.63 | -0.81 |
| EPS Diluted | -- | -- | -- | -3.00 | -1.46 |
| Normalized Diluted EPS | -- | -- | -- | -0.63 | -0.81 |
| Average Basic Shares Outstanding | -- | -- | -- | 111.29M | 84.49M |
| Average Diluted Shares Outstanding | -- | -- | -- | 111.29M | 84.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |